Heart failure & cardiomyopathies
Beta-Blocker Use and Mortality Among Patients with Systolic Heart Failure and Pacemaker Rhythm
Primary result · Mortality, pacemaker rhythm subgroupResult — go to the resultHazard ratio 0.62 CI 0.49–0.79Authors' conclusion
Beta-blocker therapy is associated with improved survival among patients with heart failure and a pacemaker rhythm on ECG.
Study context
- Population
- Patients with chronic HF with reduced EF, incl. pacemaker rhythm on baseline electrocardiogram (ECG)813 with pacemaker rhythm
- Participants
- 6,975 patients
- Comparison
- Beta-blocker therapy vs no beta-blocker
- Primary endpoint
- Mortality
Methodological detailspost hoc analysis
- Post hoc analysis
Primary result
Mortality, pacemaker rhythm subgroup
Hazard ratio
0.62
CI 0.49–0.79
P < 0.001
Beta-blockervs No beta-blocker
HR 0.62 (CI 0.49–0.79); P < 0.001
As reported in the abstract
Further findings
| Outcome | HR (CI) | P value | |
|---|---|---|---|
| Mortality, whole cohort | 0.79 (0.72–0.87) | P < 0.001 | |
| 0.512Hazard ratio (log scale) |
Mortality, whole cohort
- No interaction between beta-blockers, pacemaker rhythm and heart rate
Original publication
Beta-Blocker Use and Mortality Among Patients with Systolic Heart Failure and Pacemaker Rhythm. ESC Heart Fail. Published 30 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →